Polypharmacy in managing severe tuberculosis patients usually poses a risk of adverse drug reactions. Contezolid is a new oxazolidinone antibiotic showing good in vitro and in vivo activity against . Contezolid add-on regimen shows promising efficacy and safety results in managing severe tuberculosis patients complicated with acute thrombocytopenia.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655174 | PMC |
http://dx.doi.org/10.1002/ccr3.70001 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!